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62Allogeneic Transplantation for Pediatric Acute
Lymphoblastic Leukemia: The Emerging Role of
Peritransplantation Minimal Residual Disease/
Chimerism Monitoring and Novel Chemotherapeutic,
Molecular, and Immune Approaches Aimed at
Preventing Relapse
Michael A. Pulsipher,1 Peter Bader,2 Thomas Klingebiel,2 Laurence J. N. Cooper3Although improved donor sources and supportive care have decreased transplantation-related mortality
over the past decade, relapse remains the principal cause of failure after allogeneic transplantation for
high-risk pediatric acute lymphoblastic leukemia (ALL). Emerging tools of minimal residual disease (MRD)
and chimerism monitoring before and after transplantation have defined those children at highest risk for
relapse and provide the opportunity for intervention to prevent relapse. Specific methods aimed at decreas-
ing relapse include the use of intensive treatment before transplantation to increase the percentage of pa-
tients undergoing the procedure with negative MRD, optimal transplantation preparative regimens, and
posttransplantation interventions with targeted or immunologic therapy. Early data demonstrate decreased
relapse with the use of sirolimus for all types of ALL and imatinib for ALL with the Philadelphia chromosome
(Ph1 ALL) after transplantation. Patients with increasing chimerism or MRD have been shown to benefit
from early withdrawal of immune suppression or donor lymphocyte infusion. Finally, various targeted immu-
nologic therapies, including monoclonal antibodies, killer cell immunoglobulin-like receptor mismatching,
natural killer cell therapy, and targeted T cell therapies, are emerging that also could have an affect on relapse
and improve survival after transplantation for pediatric ALL.
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Intensive, risk-basedchemotherapy approaches cure
more than 80% of children with acute lymophoblastic
leukemia (ALL) [1-3]. Studies have identified several cy-
togenetic and response-based risk factors associated
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6/j.bbmt.2008.11.009or after relapse [4]. Although allogeneic transplantation
has been shown to benefit many children with these risk
factors, relapse rates after such transplantation remain
high, especially for the highest-risk disease states (eg,
very early relapse, CR31) [5,6]. Recently, the persis-
tence of minimal residual disease (MRD), measured by
flow cytometry or molecular methods, has been used
to further identify poor outcomes from chemotherapy
[7-9]. Preliminary studies have suggested that a similar
link exists between outcome and MRD values before
transplantation [10,11]; larger studies should more fully
illuminate the predictive power of pretransplantation
MRD in the next few years.These tools have spurred in-
vestigation into the use of approaches before and after
transplantation to achieve and sustain MRD negativity.
Such approaches include intensive chemotherapeutic
blocks using promising new agents before transplanta-
tion and such therapies as imatinib and sirolimus after
transplantation. Other approaches include withdrawal
of immune suppression and donor lymphocyte infusion
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chimerism and immune-based treatments, such as anti-
body and cellular therapies.Emerging evidence suggests
that improvedoutcomes after transplantation forpediat-
ric ALL will be seen in the next few years as clinicians
(1) define very-high-risk patients early and perform
transplantation when performance scores are high,
(2) minimize disease burden before transplantation
with cytotoxic and targeted agents, (3) use total body ir-
radiation (TBI)-based regimens that decrease the risk of
relapse for the patients at greatest risk, and (4) closely
monitor patients with MRD and/or chimerism after
transplantation, treating as necessary to minimize the
risk of relapse.INDICATIONS FOR ALLOGENEIC
TRANSPLANTATION IN PEDIATRIC ACUTE
LYMOPHOBLASTIC LEUKEMIA
Indications for transplantation for pediatric ALL
have varied through the years, based on improvements
in chemotherapy and outcomes for different risk
groups. Although international groups vary somewhat,
the Children’s Oncology Group (COG) Acute Lym-
phocytic Leukemia and Hematopoietic Stem Cell
Transplant Committees currently recommend alloge-
neic transplantation for the indications outlined in
Table 1. Indications for transplantation at first com-
plete remission (CR1) will be modified as the data ma-
ture regarding the predictive power of MRD (COGTable 1. COG Indications for Transplantation in ALL
Remission Status Indication
CR1 Alternative or sibling donors:
 Ph+ patients requiring transplantation
 Extreme hypodiploidy (< 44 chromosomes or
DNA index < 0.81)
 11q23 (MLL) plus slow early response (M2/
M3 at day 14 or MRD > 0.1% at day 29)
 Primary induction failure: M3 bone marrow at
day 29orM2bonemarroworMRD>1%atday
29 who then fail after consolidation withM2 or
M3 bone marrow or MRD > 1% at day 43
CR2 Matched sibling donor only:
 B-lineage ALL after late bone marrow relapse
($ 36 months from diagnosis)
 B-lineage ALL in after a very early isolated
extramedullary relapse (< 18 months from
diagnosis)
Alternative or sibling donors:
 B-lineage ALL after early bone marrowe
relapse (< 36 months from diagnosis)
 T-lineage ALL after bone marrow relapse at
any time
 Ph+ ALL bone marrow relapse at any time
 T-lineage ALL after very early isolated
extramedullary relapse (< 18 months from
the initiation of primary chemotherapy)
CR3 Alternative or sibling donors:
 Any B- or T-lineage patient with any type of
relapseuses flow cytometry, sensitive to 10-4) and gene array
profiles. COG investigators presented data at the
American Society of Hematology’s 2007 meeting
showing outstanding early outcomes using intensive
chemotherapy plus imatinib; thus, the role of CR1
transplantation in this group soon may be limited to
selected high-risk patients. Transplantation for infant
ALL remains controversial; COG investigators have
seen improved outcomes for both MLL rearranged
and non-MLL–rearranged infants with intensive che-
motherapy approaches [12]. Outcomes for the youn-
gest infants with MLL rearrangements remain poor,
however, and transplantation has been offered with
reasonable rates of cure when remission is obtained
[13]. The second complete remission (CR2) indica-
tions listed in Table 1 reflect the fact that some pa-
tients with late bone marrow relapse and isolated
extramedullary relapses can be successfully treated
with chemotherapy [5]. But the relatively low morbid-
ity and rates of graft-versus-host disease (GVHD) after
matched sibling transplantation, along with reports or
equivalent or better outcomes, make transplantation
a reasonable option for these patients, especially those
who cannot receive salvage chemotherapy of adequate
intensity.INTENSITYOF CHEMOTHERAPY BEFORE
TRANSPLANTATION
It has been argued that the biology of ALL at re-
lapse determines the outcome, and that patients with
sensitive disease will do well and those with resistant
disease will do poorly regardless of the pretransplan-
tation chemotherapeutic approach. Recent data from
the COG refutes this argument, showing that 71%
of patients who achieve CR after induction chemo-
therapy but have MRD positivity will experience de-
creased disease burden with subsequent intensive
blocks of chemotherapy, with nearly half of them
achieving MRD-negative status after 2 consolidation
blocks [8]. Because achieving MRD negativity before
transplantation improves long-term survival, the ma-
jor focus in the COG relapsed ALL group is to intro-
duce agents into reinduction protocols that will
increase a patient’s chance of becoming MRD-nega-
tive before transplantation. Early promising data are
emerging with the inclusion of clofarabine and epra-
tuzumab (anti-CD22 antibody) in induction/consoli-
dation approaches [14,15], and protocols including
bortezomib and temsirolimus are in the planning
stages. Optimal pretransplantation induction regi-
mens for relapsed ALL patients should maximize
the number of patients achieving MRD-negative sta-
tus, while minimizing transplantation-limiting com-
plicatons, such as organ damage and invasive fungal
infections.
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Figure 1. Early outcome data for rapamycin-based GVHD prophylaxis
after TBI-based transplantation for ALL (50 patients; median follow-up,
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TRANSPLANTATION REGIMENS FOR ACUTE
LYMOPHOBLASTIC LEUKEMIA
Fractionated TBI-based preparative regimens,
generally containing at least 1200 cGy, have been
shown to decrease the risk of relapse in high-risk
CR2 ALL transplantation recipients by as much as
27% compared with non-TBI regimens [5]. Relapse
can be further decreased by slightly higher doses of
TBI (total 1300 to 1400 cGy) or the addition
of VP-16 or thiotepa to a 1200-cGy regimen [16].
Although concerns surround the growth and develop-
mental implications of TBI use in infants or children
under age 3, several groups have been using this
approach with low rates of relapse and acceptable
growth and developmental outcomes [17]. Whether
TBI is necessary for MRD-negative, intermediate-
risk patients, in whom relapse risk is less of an issue,
is unknown.21 months). Two-year event-free survival: CR1, 92% 6 8%; CR2 IR
(bone marrow relapse . 36 months from diagnosis), 93% 6 6%; CR2
HR (bone marrow relapse, B cell,\ 36 months from diagnosis, all T
cell), 49% 6 14%; CR3, 67% 6 16%.PREVENTING RELAPSE WITH TARGETED
POSTTRANSPLANTATION THERAPIES
The use of cytotoxic therapies to maintain ALL
remission after transplantation is infeasible because of
hematologic toxicity and abrogation of the graft-
versus-leukemia (GVL) effect. However, noncytotoxic
agents (eg, molecular targeted therapies, immune
approaches) can be used successfully to help achieve
and sustain remission after transplantation. Two exam-
ples with early data are posttransplantation imatinib for
Ph1 ALL and sirolimus. Carpenter et al. [18] reported
efficacy with acceptable toxicity in early administration
of imatinib after transplantation for patients with Ph1
ALL. All 9 of the pediatric patients in their cohort (me-
dian follow-up, 1 year) are alive, with 1 relapse. COG
investigators found a reasonable toxicity profile with
imatinib started 6 months after transplantation, but
with some relapses, making the benefits of this approach
unclear. Studies evaluating the posttransplantation use
of dasatinib and nilotinib are currently underway
through the COG and Fred Hutchinson Cancer
Research Center in Seattle.
Sirolimus is a mammalian target of rapamycin
(mTOR) inhibitor that has been used for more than
15 years as an immunosuppressive agent for solid or-
gan transplantation. Several groups have reported effi-
cacy using sirolimus for GVHD prevention, and
because sirolimus has been shown to have a significant
antileukemic effect on human ALL in nonobese
diabetic–severe combined immune deficiency (NOD-
SCID) models [19], it has been used by COG investi-
gators to both control GVHD and prevent relapse.
A pilot study using sirolimus-based GVHD prophy-
laxis in pediatric ALL has shown lower rates of relapse
than expected in all risk groups (Figure 1), and a PhaseIII trial comparing sirolimus-based GVHD prophy-
laxis with standard approaches is ongoing.PERITRANSPLANTATIONMINIMALRESIDUAL
DISEASE/CHIMERISM MONITORING
Analysis of chimerism peritransplantation allows
assessment for the rare possibility of imminent graft
rejection and also can serve as an indicator for recur-
rence of underlying malignancy. In addition, character-
ization of MRD before and after transplantation has
defined those patients at greatest risk for relapse.
Consecutive posttransplantation MRD monitoring to-
gether with chimerism analysis allows the detection
of impending relapse in a substantial percentage of
children undergoing transplantation for ALL. Conse-
quently, for some groups, these analyses have served
as the basis for treatment intervention to avoid graft
rejection, maintain engraftment, and treat imminent
relapse.
DONOR LYMPHOCYTE INFUSION
Kolb et al. [20] first described the efficacy of DLI in
patients with chronic myelogenous leukemia (CML) re-
lapsing after allogeneic stem cell transplantation. DLI
initiated during frank hematologic relapse was found to
induce complete remission in 8% of patients with ALL
and in 22% of patients with acute myeloid leukemia
(AML) [21]. When tumor burden was reduced by che-
motherapy before DLI, the rate of complete response
was improved significantly (to 33% in ALL and 37%
inAML) [22].These results suggest that immunotherapy
provides the greatest benefit to patients with acute
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Figure 2. The level of MRD at the time point of further immunotherapy
determines the success rate for avoiding hematologic relapse in children
with ALL after allogeneic stem cell transplantation. Retrospective assess-
ment of quantitative characterization of MRD levels are shown in chil-
dren with ALL who received preemptive DLI on the basis of increasing
mixed chimerism.
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tered before hematologic relapse occurs. Thus, it is de-
sirable to identify those patients at greatest risk for
relapse early, to maximize the chance of successful im-
munotherapy.
TECHNIQUES FOR
POSTTRANSPLANTATION MONITORING
Twodifferent techniques are currently available for
posttransplantation surveillance of disease remission:
characterization of posttransplantation chimerism
and specific detection ofMRD.MRD assessmentmea-
sures the malignant clone directly, whereas chimerism
assessment characterizes the origin of posttransplanta-
tion hematopoiesis. Over the past decade, methods of
detectingMRD and chimerism have improved greatly,
with techniques ranging from polymerase chain reac-
tion (PCR) to immunophenotypic analysis (flow
cytometry) of aberrant cell surface molecules [23-25].
Chimerism in Leukemia
Molecular evidence of persistent or reappearing
recipient cells may be a reflection of survival of leuke-
mic cells, survival of normal host hematopoietic cells,
or a combination of both. Surviving host hematopoi-
etic cellsmay in turn facilitate the reemergence of ama-
lignant cell clone by inhibiting immunocompetent
donor effector cells. It has been shown that in patients
with CML, the reappearance of host hematopoietic
cells in the mononuclear cell fraction precedes hema-
tologic relapse [26]; thus, mixed chimerism has been
considered to reduce the GVL effect [26,27].
Several early studies left the question of whether
patients with acute leukemias and mixed chimerism
have an increased risk of relapse unanswered. In the
mid-1990s, it was realized that evolution of chimerism
is a dynamic process and that chimerismanalysis should
be done serially in short time intervals.Using short tan-
dem repeat (STR)-PCR–based serial analysis ofmicro-
satellite regions identified patients with rapidly
increasing mixed chimerism as being at the greatest
risk for relapse [22,28-31]. Investigations of subpopu-
lations of patients with acute leukemia indicated a pos-
sible difference between adult and pediatric patients.
Guimond et al. [32] demonstrated that mixed chime-
rism in T and natural killer (NK) cell subpopulations
is frequently found in pediatric patients with leukemia
relapse but not in those in remission, and also not in
adult patients with relapse. Studies performed by the
Germangroupdemonstrated that persistentmixed chi-
merism in the early posttransplantation period is
caused predominantly by normal recipient hemato-
poietic cells. An increase in recipient chimerism pre-
cedes the reappearance of the underlying disease.
These findings support the hypothesis that a state of
mixed hematopoietic chimerism may reduce the clini-cal GVL effect of alloreactive donor-derived effector
cells in patients with acute leukemias and thus facilitate
the proliferation of residual malignant cells that may
have survived the preparative regimen. Barrios et al.
[33] showed that patients with acute leukemias with in-
creasing mixed chimerism have a significantly elevated
risk of relapse. Based on the foregoing studies, several
trials were initiated to evaluate the efficacy of prevent-
ing relapse through preemptive immunotherapy on the
basis of chimerism analysis in patients with acute leuke-
mias [29,30]. A German pediatric transplantation
group showed that STR-based chimerism analysis per-
formed at regular intervals after transplantation was
able to define a subset of children with impending re-
lapse. Furthermore, overt relapse was prevented in
a portion of patients by preemptive immunotherapy
(withdrawal of immune suppression orDLI) on the ba-
sis of increasing mixed chimerism [34]. One challenge
of this approach was that it is not possible to define im-
pending relapse in all patients, because the time interval
between the conversion of chimerism and relapse can
be very short. Chimerism analysis provides informa-
tion about the alloreactivity and/or tolerance induction
of the graft and thus serves as more of a prognostic fac-
tor than an indirect marker forMRD. It is important to
stress that because of its low sensitivity (about 1%), chi-
merism analysis is not a reliable means of detecting
MRD. Consequently, basing the decision to initiate
immunotherapy solely on the results of chimerism test-
ing may result in starting immunotherapy too late.
Studies performed by the German group retro-
spectively investigated the MRD load of patients who
received DLI on the basis of increasing mixed chime-
rism. They found that patients with an MRD load of
.10-3 did not benefit from the intervention, but pa-
tients with an MRD load\ 10-3 at the start of immu-
notherapy had a survival rate of just below 40% at 2
years (Figure 2).
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A number of retrospective reports have shown that
MRD before conditioning is the strongest predictor
for relapse posttransplantation [10,11]. The Bristol
group showed that patients entering the transplanta-
tion with a high MRD load of .10-3 did not survive
their disease, whereas a portion of patients with low-
level disease (\10-3) survived, and MRD-negative pa-
tients had the best chance of survival [17]. Using the
same semiquantitative technique, a retrospective anal-
ysis of German data largely confirmed these results in
a series of 45 children. Patients with high-level MRD
at the time of transplantation (.10-3) were cured
only rarely; however, even in these high-risk patients,
additional immunotherapy posttransplantation can
eradicate residual disease. As shown in Figure 3,
a 15-year-old boy entered transplantation with an
MRD load of 1 10-3 before transplantation. After en-
graftment, he had mixed chimerism, although MRD
was undetectable at day 130. Posttransplantation im-
munosuppression was withdrawn. Because chimerism
could not be converted to complete donor status, addi-
tional DLI was given. Despite theDLI,MRDbegan to
increase; in response, a second DLI was given 50 days
later. As a consequence of these 2 DLI treatments, the
patient developed grade I GVHD, followed by a de-
crease inMRD, and eventually becameMRD-negative
3 months after the second DLI (Figure 3).
Methods for MRDmonitoring in ALL include dis-
ease-specific PCR techniques such as T cell receptor
(TCR) repertoire or immune globulin gene rearrange-
ments [35,36]. When a disease-specific marker is not
available, chimerism analysis in cell subpopulations
can be used as a surrogate marker for MRD. Thiede
et al. [37] showed that mixed chimerism in CD341 cells
is predictive of relapse in patientswithAMLandALL in
peripheral blood. They noted that increasing autolo-Time [Days]
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Figure 3. The course of a 15-year-old boy with ALL who underwent
transplantation in CR2 from a HLA-identical unrelated donor. Cyclo-
sporin was stopped when increasing mixed chimerism developed. Al-
though autologous chimerism decreased, MRD became positive. This
led to a DLI of 1 105/kg recipient weight, followed by a second infusion
of 1 106/kg after MRD did not disappear. Finally, the patient developed
grade I GVHD and becomeMRD-negative. The patient remains in remis-
sion.gous cells within this subset precedes relapse with a me-
dian interval of 52 days (range, 12 to 97 days). To enrich
this rare subpopulation, however, 50 mL of blood was
needed, which limits the applicability of this procedure
in pediatric patients. Mattsson et al. [38] performed
a prospective analysis in 30 patients with AML and
MDS. They evaluated chimerism in CD331, CD71,
and CD451 cells and found significantly more relapses
in patients whose subpopulations had mixed chimerism
compared with those who had complete donor chime-
rism [38]. In ALL patients, several studies have investi-
gated the impact of mixed chimerism after enrichment
of the cell population carrying the leukemic phenotype
and found a remarkable correlation between MRD and
mixed chimerism in the respective subset [39]. Large
studies in ALL patients assessing the predictive value
of mixed chimerism in enriched cell populations have
not yet been published, however.
Serial quantitative analysis of chimerism in whole
blood by STR-PCR allows the identification of those
patients at greatest risk for relapse. Unfortunately,
however, only a percentage of patients who relapse
can be detected, because of the often very short time
interval between the onset of mixed chimerism and re-
lapse. Therefore, it is essential to that these analyses be
performed frequently during the first 100 to 200 days
after transplantation, when most relapses occur. Per-
forming chimerism analysis in cell subpopulations
can significantly increase the sensitivity of this ap-
proach. In this setting, chimerism analysis can be con-
sidered a surrogate marker for MRD. Combining
chimerism and MRD analysis allows for documenta-
tion of engraftment and surveillance of posttransplan-
tation remission status, thus providing a rational basis
for individual preemptive immunotherapy strategies to
prevent recurrence of the underlying disease.IMMUNOTHERAPY FOR PEDIATRIC B CELL
ACUTE LYMOPHOBLASTIC LEUKEMIA
Various immune-based therapeutic approaches
currently under development may decrease relapse in
ALL, especially B-lineage ALL. Over the next decade,
the use of these therapies before (to deepen remission)
or after (to maintain remission) allogeneic transplanta-
tion procedures may produce a cure in patients
resistant to cytotoxic chemotherapy without the mor-
bidity associated with GVHD.
Antibody-Based Therapies
Therapeutic monoclonal antibodies (mAbs) have
been developed that target B-lineage cell surface anti-
gens. The COG recently reported that epratuzumab,
a humanized mAb targeting CD22 [40], administered
in combination with reinduction chemotherapy, re-
sulted in some early responses in children with
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promise in mice with B-ALL xenografts [41], and early
clinical trials using CD19-specific mAb are underway
for B-lineage lymphoma. Although targeting CD20
(with, eg, rituximab) typically is not considered for
treatment of B-ALL, CD20 is expressed in a subgroup
of de novo precursor B-ALL associated with an infe-
rior outcome compared with CD20neg B-ALL [42].
Other mAbs with potential therapeutic efficacy are be-
coming available for B-ALL, such as targeting HLA
DR and BR3, which blocks B cell-activating factor,
leading to loss of B cells [43-45]. Combinations of
mAbs (eg, anti-CD20 and anti-CD22) or mAbs with
chemotherapy may be used to improve therapeutic po-
tential for B-lineage malignancies [41,46,47]. The
therapeutic benefit of mAbs for B-ALL may be further
improved when they are used for targeted delivery of
radioimmunotherapy [45], conjugated to toxins (eg,
recombinant immunotoxin BL22, an anti-CD22 Fv
fragment fused to truncated Pseudomonas exotoxin)
[48-50] or chemotherapy [51,52], or fused to cytokines
(immunocytokine) [53]. Instead of conjugating mAbs
to toxins, investigators have ‘‘coupled’’ mAbs to T
cells. Recently, low doses of a bispecific (BiTE) mAb
(blinatumomab, MT103/MEDI-538) with a dual
specificity for CD19 on tumor cells and CD3 on unsti-
mulated T cells were found to induce an antitumor re-
sponse in patients with B-lineage non-Hodgkin
lymphoma [54]. This promising therapy also might
be applicable to the treatment of pediatric B-ALL [55].Natural Killer Cells
Human NK cells are a subset of CD561 and/or
CD161 peripheral blood lymphocytes that lack the
TCR (ie, CD3). As part of the innate immune re-
sponse,NK cells kill tumor cells independent of recog-
nition of the major histocompatibility complex
(MHC). The lack of NK cell inhibitory receptor mis-
matching (eg, killer cell immunoglobulin-like recep-
tors [KIRs] recognizing self-antigens at HLA-A, -B,
or -C loci) leads to inefficient killing of autologous tu-
mor cells, which may be overcome by engraftment of
allogeneic NK cells that sense missing expression of
donor KIR ligand(s) in the recipient and mediate
alloreactions [56]. But for adult patients with B-ALL,
relapse-free survival after T cell–depleted HLA-mis-
matched (HLA-haploidentical) hematopoietic stem
cell transplantation (HSCT) typically has not been im-
proved by KIR-ligand mismatches between donor and
recipient [57]. This may reflect the presence of inhib-
itory MHC molecules on B-ALL blasts and/or inher-
ent deficient NK cell activation [58,59]. Recent data
suggest that pediatric patients with B-ALL treated
with high proportions of alloreactive NK cells may
be sensitive to NK cell alloreactivity [60]. To harness
potential donor-versus-recipient NK cell alloreacitiv-ity, new investigational treatments (at, eg, M.D.
Anderson Cancer Center) are combining haplotype-
mismatched NK cells and epratuzumab after lympho-
depleting chemotherapy given to achieve homeostatic
expansion and prevention of immune-mediated rejec-
tion of infused allogeneic NK cells.T Cells
Approaches to children with high-risk B-ALL un-
dergoing allogeneic HSCT [61], including umbilical
cord blood transplantation (UCBT) [62], use immuno-
genetics to shape the GVL effect mediated by T cells
against B-ALL [56,63,64]. For example,HLAmatching
and mismatching can be used to reduce GVHD, and
may improve the GVL effect after UCBT [65]. In addi-
tion, genotyping of unrelated hematopoietic stem cell
donors outside the MHC loci (eg, absence in the recip-
ient of single-nucleotide polymorphisms of the nucleo-
tide-binding oligomerization domain 2/caspase
recruitment domain 15 gene) can positively affect im-
mune function, leading to improved prognoses for pa-
tients with acute leukemias, especially ALL [66]. Other
donor–recipient factors besides immunogenetics can in-
fluence the GVL effect. A recent retrospective analysis
provided preliminary evidence that persistentmicrochi-
merismofmaternal cells in individuals leads to improved
relapse-free survival (due to decreased GVHD) when
the mother is preferentially used as the haploidentical
hematopoietic stem cell donor. This is especially true
for malignancies that are not susceptible to NK cell al-
loreactivity. The beneficial effect of donor sex in haplo-
type-mismatched parent-to-child HSCT is added to,
and as pronounced as, the survival advantage associated
with haploidentical HSCT from NK cell alloreactive
donors for NK-sensitive diseases (eg, AML, pediatric
ALL) [1]. The benefit of a T cell response against
B-ALLalso is seen in data demonstrating rapid lympho-
cyte recovery after chemotherapy or HSCT [67,68].
DLIs, which are readily available, contain T cells with
a polyclonal TCR repertoire and haves been given to re-
cipientswith relapsedB-ALL [69,70], butDLI toxicities
of acute or chronicGVHDormarrow aplasia often out-
weigh the antitumor effect. However, combining DLI
with small molecules (eg, imatinib or nilotinib) after
lymphodepleting chemotherapy [71,72], intrabone in-
jections [73], graded doses of lymphocytes, DLI from
granulocyte colony-stimulating factor–mobilized do-
nors with immunosuppression [74,75], or depleting T
cell subsets [76]may be justified in clinical trials, because
curative options are rarely available for B-ALL that re-
lapses early (eg, less than 6 months) after allogeneic
HSCT [77-81].
To improve the therapeutic index ofDLI, investiga-
tors from around the world have transduced T cells to
express thymidine kinase (TK) derived fromherpes sim-
plex virus [82,83]. In the event of toxicity, conditional
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Figure 4. Immunotherapeutic Approaches Currently Being Investigated for ALL
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ciclovir. To improve specificity, allogeneic CD81 and
CD41T cells that recognize tumor-associated antigens
(TAAs) in context of MHC through endogenous ab
TCR have been selectively propagated to target B-line-
age antigens, such as intracellular HB-1 [84]. Others
have enrichedT cells reactive tominor histocompatibil-
ity antigens that are present on recipient blasts, but not
normal donor hematopoietic cells [85-88]. Immune
tolerance typically precludes the ability of autologous
T cells to recognize TAAs in the context of MHC in
B-ALL. In addition, antigen-specific T cells may not
be able lyse B-ALL blasts. Consequently, many investi-
gators have redirected T cell specificity through the ge-
netic introduction of chimeric antigen receptors (CARs)
that recognize CD19 expressed on B-ALL, including
cancer stem cells [89] and normal B cells [90-92]. Phase
I trials are now reporting on the safety and feasibility of
this gene therapy approach, and clinical trials of next-
generation CARs and gene-transfer approaches for B-
ALL are being planned [93].
Vaccines
MHC class I and II molecules on allogeneic B-ALL
blasts can directly present TAAs to donor-derived
CD81 and CD41 T cells, respectively. For example,
the leukemia-associated Wilms’ tumor antigen (WT1)
is immunogenic, raising the possibility that WT1
vaccines can be used to augment immunity [94,95]. In
addition, fusion genes, such as BCR-ABL in P1
B-ALL, may serve as a neoantigen that can be targeted
by tumor-specific T cells [96]. B-ALL blasts generally
lack costimulatory molecules, such as CD80/CD86, to
complete a fully competent T cell activation signal. To
augment the immune response, investigators have ex-
plored active immunization for B-ALL using autolo-
gous dendritic cells pulsed with peptides from TAAs
derived from B-ALL [97,98]. Alternatively, autologous
tumor cells themselves, possibly infused with accessorycells such as skin fibroblasts, can be geneticallymodified
to enforce expression of costimulatory molecules, such
as CD40 ligand (and interleukin-2), to serve as a source
of antigen-presenting cells [99,100].FUTURE OF IMMUNOTHERAPY FOR
PEDIATRIC ALL
Despite the irony that a dysregulated immune re-
sponse to infection early in life may lead to childhood
B-ALL [101], pediatric oncologists now have many op-
portunities tomanipulate the immune system (Figure 4)
to achieve a lasting anti-B-ALL effect. Immunotherapy
may be more effective during a MRD state after bone
marrow transplantation, and allogeneic transplantation
offers an opportunity to target specific minor histocom-
patibility antigens or to useKIR antigenmismatching to
direct immune reactions to cancer cells. To move im-
mune-based treatments into widespread practice, coop-
erative groups and biopharmaceutical companies need
to emphasize the systematic testing of promising immu-
notherapies in children with high-risk or relapsed
B-ALL, and pediatric oncology fellowships need to in-
corporate a thorough understanding of the immune sys-
tem into their training programs. This approach will
help build a future inwhich immunotherapies can be de-
signed rationally and combinations of therapies can be
delivered to improve overall survival and decrease the
cost of survivorship of pediatric B-ALL.CONCLUSION
As chemotherapy for ALL in children improves,
the patients with ALL who benefit from transplanta-
tion will have a disease that is largely resistant to cyto-
toxic approaches. Minimizing the disease burden,
administering optimal regimens, closely following pa-
tients withMRD techniques, and treating when neces-
sary with targeted and immune-based approaches may
Biol Blood Marrow Transplant 15:62-71, 2009 69Allogeneic Transplantation for Pediatric ALLdecrease relapse and improve survival. As these ap-
proaches improve, children unable to obtain remission
who currently benefit little from transplantation ap-
proaches also may experience improved survival.ACKNOWLEDGMENTS
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